Table 1.
Overview of the articles published on mortality and hypopituitarism without growth hormone replacement therapy
| Reference and country | Etiology | Study population (no.) and mean age* | Controls | Follow-up duration† | Conclusions |
|---|---|---|---|---|---|
| Rosen & Bengtsson (1990) [5] Sweden |
Hypopituitarism including 10% craniopharyngioma; Acromegaly + CD excluded; GHD 16% tested, of which 100% GHD |
333 (W 129, M 204) 43.1/48.6 yr |
General population | ± 30 yr |
All-cause death rate: 104 vs. 57.4 (P < 0.001) W: 41 vs. 14.5, M: 63 vs. 42.9; CV death rate: 60 vs. 30.8 (P < 0.001) W: 20 vs. 7.4, M: 40 vs. 23.5; Malignancy death rate: 7 vs. 14.2 W: 4 vs. 4.1 (P = 0.056), M: 3 vs. 10.1 (P < 0.02) |
| Bates et al. (1996) [7] UK |
Hypopituitarism including 13% extrapituitary tumor; Acromegaly + CD excluded; GHD 55% tested, of which 96% GHD |
172 (W 70, M 102) 52 yr |
General population | NR |
All-cause mortality SMR: 1.73 (95% CI 1.28–2.18) W: 2.29 (95% CI 1.37–3.58), M: 1.50 (95% CI 1.02–2.13); CV mortality SMR: 1.35 (95% CI 0.84–2.07) W: 1.46 (95% CI 0.50–3.20, ), M: 1.32 (95% CI 0.74–2.17); Malignancy mortality SMR: 1.41 (95% CI 0.73–2.47) W: 3.21 (95% CI 1.46–6.11), M: 0.53 (95% CI 0.11–1.54) |
| Bulow et al. (1997) [6] Sweden |
Hypopituitarism including 12% craniopharyngioma; Acromegaly + CD excluded; GHD 18% tested, of which 90% GHD |
344 (W 130, M 214) 52 yr |
General population | 11.9 yr |
All-cause mortality SMR: 2.17 (95% CI 1.88–2.51) W: 2.93 (95% CI 2.28–3.75), M: 1.91 (95% CI 1.59–2.28); CV mortality SMR: 1.75 (95% CI 1.40–2.19); CVA mortality SMR: 3.39 (95% CI 2.27–4.99) W: 4.91 (95% CI 2.62–8.40), M: 2.64 (95% CI 1.44–4.42); Cardiac mortality SMR: 1.41 (1.04–1.88) |
| Tomlinson et al. (2001) [10] UK |
Hypopituitarism including 12% craniopharyngioma; Acromegaly + CD excluded; GHD 11% tested, of which 100% GHD |
1014 (W 500, M 514) 45.3/46.2 yr |
General population | 8 yr |
All-cause mortality SMR: 1.87 (95% CI 1.62–2.16) W: 2.29 (95% CI 1.75–3.00), M: 1.57 (95% CI 1.19–2.06); CV mortality SMR: 1.82 (P < 0.001); CVA mortality SMR: 2.44 (P < 0.001); Malignancy mortality SMR: 0.97 (P = 0.6) |
| Svensson et al. (2004) [20] Sweden |
Hypopituitarism (no further data); Acromegaly + CD excluded; No GHD data |
1411 (W 664, M 747) 56.9 yr |
General population | 5 yr |
All-cause mortality SMR: 3.80 (95% CI 3.43–4.19) W: 4.54 (95% CI 3.89–5.26), M: 3.36 (95% CI 2.93–3.83); Malignancy mortality SMR: 3.92 (95% CI 3.21–4.76) W: 4.49 (95% CI 3.26–6.03), M: 3.59 (95% CI 2.74–4.63) |
*Mean age given for total population or by sex
†Mean or median
CD: Cushing’s disease; CI: confidence interval; CV: cardiovascular; CVA: cerebrovascular accident; GHD: growth hormone deficiency; M: men; NR: not reported; SMR: standardized mortality ratio; W: women; yr: year